



ASX ANNOUNCEMENT

Closure of A\$5.0 Million Loan Facility with Major Shareholders

MELBOURNE, Australia (02 July 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has today closed down the A\$5.0 million secured Loan Agreement (“Loan Facility”) with major shareholders Tenmile Ventures Pty Ltd (“Tenmile”) and Ryder Capital Management Pty Ltd (“Ryder Capital”).

The Loan Facility was established on 9 September 2025 and was designed to provide working capital flexibility as Lumos progressed towards the granting of a CLIA waiver from the U.S. FDA for its flagship test, FebriDx®.

Commenting on the announcement, Doug Ward, CEO of Lumos Diagnostics said: *“The Company sincerely appreciates the financial support provided by Tenmile and Ryder Capital, with this loan provided as a bridge while Lumos progressed its application toward the transformative and successful granting of CLIA waiver for FebriDx®. Now well-funded, Lumos was in a position to close out this loan, release the security and accelerate the U.S. commercialisation of FebriDx®.”*

Lumos had previously drawn A\$1.0 million under the Loan Facility, with A\$4.0 million being unused. Following the completion and receipt of the A\$20.0 million placement proceeds in April 2026, the outstanding balance was repaid in full, including accrued interest, as previously advised for use of funds at the time of the capital raise.

As at the date of this announcement, the Company has no debt, and the security interests held by the lenders pursuant to the Loan Facility have now been released.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598